Corynebacterium diphtheriae: Understanding Diphtheria

When a bacterium carries the power to create a leathery membrane in your throat that can silently suffocate you, understanding its nature becomes critical. Corynebacterium diphtheriae, the pathogen behind diphtheria, represents one of medicine’s most formidable challenges. Though vaccination has dramatically reduced its impact, this bacterium remains a threat in areas with low immunization coverage and serves as an important subject for nursing students to understand thoroughly.

The discovery that changed medical history 🔗

In 1883, German bacteriologist Edwin Klebs first identified the bacterium in pseudomembranes from diphtheria patients. The following year, his colleague Friedrich Loeffler successfully cultured the organism and made a groundbreaking observation: the bacteria remained confined to the throat and nasal passages, yet they caused severe damage to distant organs. This led Loeffler to propose that the bacteria produced a soluble toxin responsible for the systemic effects. By 1888, French scientists Émile Roux and Alexandre Yersin confirmed this hypothesis by demonstrating that sterile filtrates from bacterial cultures could reproduce the disease in animals, establishing diphtheria as the first recognized toxin-mediated infectious disease.

Bacterial characteristics and growth requirements 🔗

Corynebacterium diphtheriae is a Gram-positive bacillus with distinctive features that aid in its identification. The bacteria appear as slender, club-shaped rods measuring approximately 3-6 micrometers in length. Under the microscope, they display a characteristic arrangement often described as resembling Chinese letters or a palisade fence due to their unique pattern of division.

These bacteria are non-motile, non-spore-forming, and aerobic organisms. One notable feature is their metachromatic granules, also called Babes-Ernst granules, which appear as dark spots when stained with methylene blue. These granules contain stored nutrients and help distinguish C. diphtheriae from other bacteria.

Growth media and cultural variants 🔗

Unlike many common bacteria, C. diphtheriae requires special enrichment media for optimal growth. Loeffler’s medium, containing serum, preferentially supports the growth of these bacteria. For identification purposes, tellurite agar serves as a differential medium where C. diphtheriae colonies develop a characteristic black halo due to tellurite reduction.

Based on colony appearance and biochemical properties, four biotypes exist: gravis, mitis, intermedius, and belfanti. The gravis strain exhibits the fastest growth rate with a generation time of about 60 minutes, while the mitis strain grows more slowly at approximately 180 minutes. These growth differences influence how quickly the bacteria can establish infection and produce toxin in the human body.

The toxin that defines the disease 🔗

The pathogenic power of C. diphtheriae comes not from tissue invasion but from toxin production. Interestingly, not all strains produce this deadly toxin. The ability to manufacture diphtheria toxin depends on infection by a specific bacteriophage carrying the tox gene, a phenomenon called lysogenic conversion. Non-toxigenic strains can become toxigenic when infected by this bacteriophage, and conversely, toxigenic strains can lose their toxin-producing ability if cured of the phage.

The diphtheria toxin is remarkably potent, with a lethal dose of less than 0.1 micrograms per kilogram of body weight. This protein functions by inhibiting protein synthesis in human cells, leading to cell death. The toxin consists of three domains: a catalytic portion that damages cells, a transmembrane segment that allows entry into cells, and a receptor-binding domain that targets specific tissues.

Clinical manifestations and disease progression 🔗

Respiratory diphtheria 🔗

When toxigenic C. diphtheriae colonizes the upper respiratory tract, symptoms typically begin 2-5 days after exposure. Initial manifestations include sore throat, fever, malaise, and difficulty swallowing. The hallmark feature develops within 2-3 days: a thick, grayish-white pseudomembrane forms over the tonsils, pharynx, or larynx.

This pseudomembrane, from which the disease derives its Greek name meaning “leather hide,” consists of dead tissue, fibrin, bacteria, and inflammatory cells. It adheres firmly to underlying tissues and bleeds when attempts are made to remove it. If the membrane extends to the larynx and trachea, it can cause airway obstruction, creating the respiratory emergency that historically gave diphtheria its nickname as the “strangling angel of children.”

Cutaneous diphtheria 🔗

C. diphtheriae can also infect skin wounds, surgical sites, or pre-existing skin lesions. Cutaneous diphtheria typically presents as chronic, non-healing ulcers with a gray membrane. While generally less severe than respiratory disease, skin infections can still produce toxin and lead to systemic complications.

Life-threatening complications 🔗

The systemic effects of diphtheria toxin create the most serious complications. Myocarditis develops in approximately 10-25% of patients, typically during the acute phase or within weeks following infection. The toxin damages heart muscle fibers, potentially causing abnormal heart rhythms, heart failure, and sudden death. Pathological examination reveals extensive tissue degeneration with infiltration of inflammatory cells.

Neurological complications affect up to 75% of patients with severe disease. The toxin targets Schwann cells that produce myelin around nerves, leading to demyelination and nerve dysfunction. Early changes involve widening of nodes of Ranvier and structural alterations in nerve configuration. Patients may experience paralysis of cranial nerves, affecting swallowing and eye movements, or develop polyneuropathy affecting limbs and respiratory muscles. Diaphragm paralysis can lead to respiratory failure requiring mechanical ventilation.

Diagnostic approaches 🔗

Diagnosis begins with clinical suspicion based on characteristic findings. Healthcare providers should consider diphtheria in patients presenting with pharyngitis accompanied by membrane formation, especially in those with incomplete vaccination or recent travel to endemic areas.

Laboratory confirmation 🔗

Collection of specimens from beneath the pseudomembrane or from the nasopharynx provides material for culture. Swabs from skin lesions are obtained for cutaneous cases. Growing bacteria takes time, and if C. diphtheriae are identified, additional testing determines whether they produce toxin, which is the only definitive way to confirm diphtheria.

The Elek immunoprecipitation test remains the standard phenotypic method for detecting toxin production, with results available in 16-24 hours. Real-time PCR assays can detect the toxin gene more rapidly, though positive results require confirmation with the Elek test due to rare non-toxigenic strains carrying the tox gene.

Culture requires tellurite-containing media, and isolates should be sent to reference laboratories for toxigenicity testing. Because bacterial growth and toxin testing take time, treatment should never be delayed while awaiting laboratory confirmation.

Treatment strategies 🔗

Successful management of diphtheria requires rapid intervention. Once diphtheria is suspected, treatment begins immediately without waiting for laboratory results. Patients require isolation using droplet precautions to prevent transmission.

Diphtheria antitoxin 🔗

The cornerstone of treatment is diphtheria antitoxin, which neutralizes circulating toxin before it binds to cells. However, antitoxin cannot reverse damage once toxin has entered cells, making early administration critical. For unvaccinated individuals without proper treatment, diphtheria can be fatal in around 30% of cases, with young children at higher risk. In the United States, antitoxin must be obtained from the CDC through an investigational protocol.

The antitoxin is derived from horse serum and carries a small risk of allergic reactions, including anaphylaxis in less than 1% of patients. Healthcare providers must perform sensitivity testing before administration and have emergency equipment readily available.

Antibiotic therapy 🔗

Antibiotics serve multiple purposes: eliminating the bacteria, stopping toxin production, and preventing transmission. Penicillin or erythromycin are the primary choices, administered for 14 days. Patients are considered non-infectious after 48 hours of antibiotic therapy, but confirmation requires two negative cultures taken 24 hours apart after completing treatment.

Supportive care 🔗

Close monitoring for complications is essential. Cardiac monitoring detects arrhythmias early, and temporary pacemakers may be necessary for heart block. Respiratory support becomes critical if airway obstruction or diaphragm paralysis develops. Some patients require tracheostomy or mechanical ventilation.

Prevention through vaccination 🔗

Vaccination represents the most effective strategy against diphtheria. The vaccine contains diphtheria toxoid, a chemically modified toxin that stimulates immunity without causing disease. In 2023, an estimated 84% of children worldwide received the recommended three doses of diphtheria-containing vaccine during infancy, though 16% remained unprotected with wide coverage variation between countries.

The standard vaccination schedule includes multiple doses starting at 6 weeks of age, with booster doses in adolescence and adulthood. The vaccine is typically administered as DTaP (diphtheria, tetanus, and pertussis) for children or Tdap for adolescents and adults. Importantly, having diphtheria does not confer lasting immunity, so recovered patients should still receive vaccination during convalescence.

Close contacts of confirmed cases require antibiotic prophylaxis and should verify their vaccination status, receiving booster doses if their last vaccine was more than five years prior.

What do you think? How might understanding the unique pathogenesis of C. diphtheriae influence your approach to patient education about vaccination? In what ways could the historical lessons from diphtheria’s toxin-mediated disease mechanism inform current nursing practice when encountering other toxin-producing bacterial infections?

References

1. https://www.cdc.gov/diphtheria/about/index.html
2. https://www.ncbi.nlm.nih.gov/books/NBK560911/
3. https://www.who.int/news-room/fact-sheets/detail/diphtheria
4. https://www.cdc.gov/diphtheria/hcp/clinical-guidance/index.html